PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of wjgLink to Publisher's site
 
World J Gastroenterol. 2010 December 28; 16(48): 6098–6103.
Published online 2010 December 28. doi:  10.3748/wjg.v16.i48.6098
PMCID: PMC3012570

Current protective strategies in liver surgery

Abstract

During liver resection surgery for cancer or liver transplantation, the liver is subject to ischaemia (reduction in blood flow) followed by reperfusion (restoration of blood flow), which results in liver injury [ischemia-reperfusion (IR) or IR injury]. Modulation of IR injury can be achieved in various ways. These include hypothermia, ischaemic preconditioning (IPC) (brief cycles of ischaemia followed by reperfusion of the organ before the prolonged period of ischaemia i.e. a conditioning response), ischaemic postconditioning (conditioning after the prolonged period of ischaemia but before the reperfusion), pharmacological agents to decrease IR injury, genetic modulation of IR injury, and machine perfusion (pulsatile perfusion). Hypothermia decreases the metabolic functions and the oxygen consumption of organs. Static cold storage in University of Wisconsin solution reduces IR injury and has prolonged organ storage and improved the function of transplanted grafts. There is currently no evidence for any clinical advantage in the use of alternate solutions for static cold storage. Although experimental data from animal models suggest that IPC, ischaemic postconditioning, various pharmacological agents, gene therapy, and machine perfusion decrease IR injury, none of these interventions can be recommended in clinical practice. This is because of the lack of randomized controlled trials assessing the safety and efficacy of ischaemic postconditioning, gene therapy, and machine perfusion. Randomized controlled trials and systematic reviews of randomized controlled trials assessing the safety and efficacy of IPC and various pharmacological agents have demonstrated biochemical or histological improvements but this has not translated to clinical benefit. Further well designed randomized controlled trials are necessary to assess the various new protective strategies in liver resection.

Keywords: Liver, Hepatectomy, Liver transplantation, Ischemia-reperfusion injury, Hypothermia, Ischaemic preconditioning

INTRODUCTION

Approximately 11 000 liver transplantations and an estimated 7000 to 10 000 liver resections are performed every year in US[1-3]. During liver resection and transplantation, the liver is subject to ischaemia (reduction in blood flow). A period of ischaemia is unavoidable in organ transplantation between the time the donor heart stops pumping blood through the circulation and the circulation to the organ is restored in the recipient. When the blood flow is restored (reperfusion), the liver is subjected to further injury. The damage caused by ischemia and then reperfusion in an organ is called ischemia-reperfusion injury (IR injury).

MECHANISM OF IR INJURY

The mechanisms involved in the production of the tissue damage by the IR injury are complex. Overviews of the mechanisms involved in liver IR injury have been described by various authors[4-6]. In simple terms, the sequence of ischaemia followed by reperfusion results in the activation of Kupffer cells (liver macrophages) and polymorphonucleocytes resulting in the production of reactive oxygen species (ROS), cytokines, and adhesion molecule activation leading to liver parenchymal damage.

PROTECTIVE STRATEGIES TO DECREASE LIVER IR INJURY

Modulation of IR injury can be achieved in various ways. These include hypothermia[7,8], ischaemic preconditioning (IPC)[9,10], ischaemic postconditioning[11], pharmacological agents to decrease IR injury[12,13], genetic modulation of IR injury[14], and machine perfusion[7,15]. Systematic reviews of well designed randomized controlled trials (with homogeneity) are currently considered the highest level of evidence to assess the effects of interventions[16]. A well designed randomized controlled trial is the next highest level of evidence[16]. The safety and effectiveness of the different interventions based on randomized controlled trials and systematic reviews of randomized controlled trials in humans is discussed under each of the methods.

Hypothermia

Hypothermia decreases the metabolic functions and the oxygen consumption of organs[17]. Although the organ can be preserved by warm perfusion, hypothermia has been used to decrease IR injury in the transplantation setting for several decades.

Invasive cooling of the donor liver: Ischaemic injury to the liver begins when the donor heart stops pumping blood through the circulation. During the liver retrieval operation, current standard practice involves perfusion of the liver through the aorta with or without perfusion through the portal vein using cold solution[18]. There are no randomized controlled trials comparing hypothermic with normothermic perfusion of the donor organ. Currently, there is evidence from one randomized controlled trial that the incidence of primary graft non-function decreases when double perfusion (aortic and portal vein perfusion) is used compared with single perfusion (aorta alone perfusion) in marginal donors (sub-optimal donors)[18]. In the optimal donor, there is currently no evidence of difference in clinical outcomes between single perfusion and double perfusion[18]. Apart from this comparison of the donor perfusion technique, there is currently no evidence for any difference in the graft or patient survival between the different solutions used for donor perfusion or different pressures used for perfusion[19-21].

Surface cooling of donor liver: There is currently no evidence that surface cooling of the donor liver in addition to invasive cooling by aortic and portal vein perfusion improves liver transplant outcomes.

Static cold storage and storage solutions: After removal of the liver from the cadaver, the liver is stored for a few hours till it can be transplanted to the recipient. This is the time required for the transport of the liver from the retrieval site to the transplant site. During this time, preservation injury occurs. This is because of lack of adequate oxygenation of the tissues. The current standard method for preservation is static cold storage. There have been no randomized controlled trials comparing static cold storage with other methods of organ preservation during transport of the liver. However, static cold storage remains the standard against which all other organ preservation methods can be compared. The introduction of University of Wisconsin (UW) solution in 1988[22] increased the capability of long distance procurement and sharing and decreased the costs associated with long distance procurement by decreasing the preservation injury[23,24]. Although the efficacy of UW solution compared with other solutions available at that time (Collin’s solution) was not assessed by randomized controlled trial, the evidence for the benefits of UW solution over Collin’s solution was so overwhelming[23,24] that a randomized controlled trial would have been considered unethical. To date, UW solution has remained the gold standard solution against which all other solutions are compared[25]. There is no evidence from randomized controlled trials that any of the other solutions such as Celsior solution or histidine-tryptophan-ketoglutarate solution result in a better graft or patient survival than UW solution[26-30].

Hypothermia in liver resections: While hypothermia has been used as the standard method of decreasing IR injury in liver transplantation, the role of hypothermia as a method of decreasing IR injury in liver resection surgery has not been established. The only randomized controlled trial assessing the impact of in-situ hypothermia in liver resections failed to demonstrate any major clinical benefits of in-situ hypothermia[8].

IPC

IPC is the mechanism by which brief periods of ischaemia followed by reperfusion of the organ results in the ability of the organ to withstand a subsequent prolonged period of ischaemia[31]. Overviews of the mechanisms of IPC have been provided by various authors[5,6,32,33]. Adenosine and nitric oxide play a pivotal role in the IPC response.

IPC can be achieved by a local preconditioning stimulus (direct IPC)[9,10] or by a remote stimulus (remote IPC)[6,34,35]. Remote IPC (RIPC) is the mechanism by which IPC of one vascular bed (area supplied by one artery) protects another vascular bed (area supplied by another artery) from IR injury[35]. The mechanisms involved in RIPC have been reviewed previously[6,34]. Currently, both neural and humoral pathways are believed to be involved in RIPC.

There is experimental evidence that direct IPC and RIPC protects against liver IR injury in the animal model[36-38]. In humans, a systematic review of randomized controlled trials showed that direct IPC decreases the enzyme markers of liver parenchymal injury after liver resections performed under vascular control (i.e. temporary occlusion of blood vessels supplying the liver)[9]. However, this did not translate into any clinical benefit[9]. One randomized controlled trial of remote IPC demonstrated a similar finding i.e. a decrease in the enzyme markers of liver parenchymal injury after liver resections without demonstrating any clinical benefit[39]. There is no evidence for benefit from direct IPC in liver transplantation based on a systematic review of randomized controlled trials[10]. Currently, there are no published randomized controlled trials of RIPC in liver transplantation. Thus, routine IPC (direct IPC or remote IPC) cannot be recommended in either liver resection or transplantation.

Ischaemic postconditioning

As opposed to IPC where the conditioning stimulus is applied prior to the prolonged period of ischaemia, ischaemic postconditioning (IPost) involves the application of the conditioning stimulus (brief intermittent cycles of IR) after the prolonged period of ischaemia but prior to permanent reperfusion i.e. ischaemia followed by conditioning stimulus followed by permanent restoration of blood flow[11]. Overviews of the mechanisms of ischaemic postconditioning have been reviewed previously[40,41]. As with IPC, adenosine and nitric oxide play a pivotal role in ischaemic postconditioning. As in the case of IPC, ischaemic post-conditioning can also be achieved by a local postconditioning stimulus (direct IPost)[11,42-44] or by a remote postconditioning stimulus (RIPost)[45].

In animal models, there is experimental evidence that IPost protects against liver IR injury[42-44]. There are currently no randomized controlled trials of ischaemic postconditioning (direct or remote) in either liver resection or liver transplantation. So, routine ischaemic postconditioning (direct IPost or RIPost) cannot be currently recommended in either liver resection or liver transplantation.

Pharmacologic interventions to decrease IR injury

Various pharmacologic interventions have been attempted with an intention of decreasing IR injury. Considering that ROS and inflammatory mediators play significant roles in IR injury[4-6], pharmacological interventions to neutralise or modulate the pathways using antioxidants and steroids are a subject of significant research[13].

There is experimental evidence that some pharmacological interventions[46,47] protect against liver IR injury in the animal model. In humans, a systematic review of randomized controlled trials assessing the role of pharmacologic interventions in decreasing IR injury after liver resections showed that some interventions such as methyl prednisolone decrease the enzyme markers of liver parenchymal injury after liver resections but without demonstrating evidence of clinical benefit[13]. The role of numerous pharmacological interventions in decreasing IR injury in liver transplantation has been investigated[48-77]. None of the interventions have shown any benefit in graft or patient survival.

Genetic modulation of IR injury

As the molecular mechanisms of IR injury are increasingly understood, more research is being performed on the genetic modulation of the pathways in IR injury both for better understanding of the mechanisms involved in IR injury and for potential therapeutic applications[78]. Experimental evidence to demonstrate the potential role of genetic modulation of liver IR injury exists[14]. There are no randomized clinical trials assessing the impact of genetic modulation of IR injury in liver resections or liver transplantation.

Machine perfusion

Machine perfusion involves pulsatile perfusion of the liver using a machine as opposed to static cold storage. This can be performed by perfusing the liver with a hypothermic perfusate[79] or with a normothermic perfusate[80]. There is experimental evidence in animal models that machine perfusion protects against liver IR injury[80,81]. The safety and efficacy of machine perfusion compared to static cold storage to decrease liver IR injury is yet to be assessed in humans by randomized controlled trials.

DIFFERENCES IN RESULTS BETWEEN ANIMAL MODELS AND HUMAN TRIALS

As discussed above, there are major differences in the results of the role of the different interventions in decreasing liver IR injury between animal models and clinical results. Some possible reasons for this include the lack of fidelity of the model used (i.e. how truly are the results transferable from the model to humans)[82], the use of unvalidated surrogate outcomes, and the use of inadequate sample size in human trials.

FUTURE TRIALS

Future trials of adequate sample size and low risk of bias (low risk of prejudice towards the treatment arm or the control arm)[83] should be performed to decrease the random errors (arriving at wrong conclusions because of pure chance, usually due to inadequate sample size) and systematic errors (arriving at wrong conclusions because of prejudice towards the treatment or the control arm). Measurement of meaningful differences in clinical outcomes requires a large trial. Development and validation of composite outcomes and surrogate outcomes will enable evaluation of the interventions using a smaller sample size.

CONCLUSION

Currently, the only intervention that has shown to be beneficial in the protection of the liver during liver transplantation is hypothermia. In liver resection surgery, there is currently no established intervention targeted at modulating IR injury that provides any major clinical benefit. However, many new therapies and targets are being discovered. Well designed randomized controlled trials are necessary to assess the new protective strategies in liver resection and liver transplantation.

Footnotes

Peer reviewer: Marco Vivarelli, MD, Assistant Professor, Department of Surgery and Transplantation, University of Bologna, S. Orsola Hospital, Bologna 40123, Italy

S- Editor Sun H L- Editor O'Neill M E- Editor Lin YP

References

1. OPTN/SRTR. OPTN/SRTR 2008 Annual report. Liver characteristics. 2010 Accessed on March 27, 2010. Available from: http://www.ustransplant.org/annual_reports/current/908a_li.pdf.
2. Asiyanbola B, Chang D, Gleisner AL, Nathan H, Choti MA, Schulick RD, Pawlik TM. Operative mortality after hepatic resection: are literature-based rates broadly applicable? J Gastrointest Surg. 2008;12:842–851. [PubMed]
3. Dimick JB, Wainess RM, Cowan JA, Upchurch GR Jr, Knol JA, Colletti LM. National trends in the use and outcomes of hepatic resection. J Am Coll Surg. 2004;199:31–38. [PubMed]
4. Vardanian AJ, Busuttil RW, Kupiec-Weglinski JW. Molecular mediators of liver ischemia and reperfusion injury: a brief review. Mol Med. 2008;14:337–345. [PMC free article] [PubMed]
5. Koti RS, Seifalian AM, Davidson BR. Protection of the liver by ischemic preconditioning: a review of mechanisms and clinical applications. Dig Surg. 2003;20:383–396. [PubMed]
6. Tapuria N, Kumar Y, Habib MM, Abu Amara M, Seifalian AM, Davidson BR. Remote ischemic preconditioning: a novel protective method from ischemia reperfusion injury--a review. J Surg Res. 2008;150:304–330. [PubMed]
7. Lee CY, Mangino MJ. Preservation methods for kidney and liver. Organogenesis. 2009;5:105–112. [PMC free article] [PubMed]
8. Kim YI, Hiratsuka K, Kitano S, Joo DH, Kamada N, Sugimachi K. Simple in situ hypothermia reduced ischaemic injury to human liver during hepatectomy. Eur J Surg. 1996;162:717–721. [PubMed]
9. Gurusamy KS, Kumar Y, Pamecha V, Sharma D, Davidson BR. Ischaemic pre-conditioning for elective liver resections performed under vascular occlusion. Cochrane Database Syst Rev. 2009:CD007629. [PubMed]
10. Gurusamy KS, Kumar Y, Sharma D, Davidson BR. Ischaemic preconditioning for liver transplantation. Cochrane Database Syst Rev. 2008:CD006315. [PubMed]
11. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285:H579–H588. [PubMed]
12. Abu-Amara M, Gurusamy KS, Glantzounis G, Fuller B, Davidson BR. Pharmacological interventions for ischaemia reperfusion injury in liver resection surgery performed under vascular control. Cochrane Database Syst Rev. 2009:CD008154. [PubMed]
13. Abu-Amara M, Gurusamy KS, Hori S, Glantzounis G, Fuller B, Davidson BR. Pharmacological interventions versus no pharmacological intervention for ischaemia reperfusion injury in liver resection surgery performed under vascular control. Cochrane Database Syst Rev. 2009:CD007472. [PubMed]
14. Li X, Zhang JF, Lu MQ, Yang Y, Xu C, Li H, Wang GS, Cai CJ, Chen GH. Alleviation of ischemia-reperfusion injury in rat liver transplantation by induction of small interference RNA targeting Fas. Langenbecks Arch Surg. 2007;392:345–351. [PubMed]
15. Monbaliu D, Brassil J. Machine perfusion of the liver: past, present and future. Curr Opin Organ Transplant. 2010;15:160–166. [PubMed]
16. Oxford Centre for Evidence-Based Medicine. Levels of Evidence. 2009 Accessed on March 24, 2010. Available from: http://www.cebm.net/index.aspx?o=1025.
17. Polderman KH. Mechanisms of action, physiological effects, and complications of hypothermia. Crit Care Med. 2009;37:S186–S202. [PubMed]
18. D'Amico F, Vitale A, Gringeri E, Valmasoni M, Carraro A, Brolese A, Zanus G, Boccagni P, D'Amico DF, Cillo U. Liver transplantation using suboptimal grafts: impact of donor harvesting technique. Liver Transpl. 2007;13:1444–1450. [PubMed]
19. Cofer JB, Klintmalm GB, Morris CV, Solomon H, Watemberg IA, Husberg BS, Jennings LW. A prospective randomized trial between Euro-Collins and University of Wisconsin solutions as the initial flush in hepatic allograft procurement. Transplantation. 1992;53:995–998. [PubMed]
20. Iaria G, Tisone G, Pisani F, Buonomo O, Camplone C, Pollicita S, Torri E, Anselmo A, Casciani CU. High-pressure perfusion versus gravity perfusion in liver harvesting: results from a prospective randomized study. Transplant Proc. 2001;33:957–958. [PubMed]
21. Schwartz ME, Nishizaki T, Thung SN, Manzarbeitia C, Maharajh A, Gordon R, Miller CM. Initial flush solution for donor liver procurement: lactated Ringers' or UW solution? A randomized, prospective trial. Transplant Proc. 1991;23:1554–1556. [PubMed]
22. Kalayoglu M, Sollinger HW, Stratta RJ, D'Alessandro AM, Hoffmann RM, Pirsch JD, Belzer FO. Extended preservation of the liver for clinical transplantation. Lancet. 1988;1:617–619. [PubMed]
23. Stratta RJ, Wood RP, Langnas AN, Duckworth RM, Markin RS, Marujo W, Grazi GL, Saito S, Dawidson I, Rikkers LF. The impact of extended preservation on clinical liver transplantation. Transplantation. 1990;50:438–443. [PubMed]
24. Ploeg RJ. Preliminary results of the European Multicenter Study on UW solution in liver transplantation. The Study Group. Transplant Proc. 1990;22:2185–2188. [PubMed]
25. Lopez-Andujar R, Deusa S, Montalvá E, San Juan F, Moya A, Pareja E, DeJuan M, Berenguer M, Prieto M, Mir J. Comparative prospective study of two liver graft preservation solutions: University of Wisconsin and Celsior. Liver Transpl. 2009;15:1709–1717. [PubMed]
26. García-Gil FA, Arenas J, Güemes A, Esteban E, Tomé-Zelaya E, Lamata F, Sousa R, Jiménez A, Barrao ME, Serrano MT. Preservation of the liver graft with Celsior solution. Transplant Proc. 2006;38:2385–2388. [PubMed]
27. Meine MH, Zanotelli ML, Neumann J, Kiss G, de Jesus Grezzana T, Leipnitz I, Schlindwein ES, Fleck A Jr, Gleisner AL, de Mello Brandão A, et al. Randomized clinical assay for hepatic grafts preservation with University of Wisconsin or histidine-tryptophan-ketoglutarate solutions in liver transplantation. Transplant Proc. 2006;38:1872–1875. [PubMed]
28. Pedotti P, Cardillo M, Rigotti P, Gerunda G, Merenda R, Cillo U, Zanus G, Baccarani U, Berardinelli ML, Boschiero L, et al. A comparative prospective study of two available solutions for kidney and liver preservation. Transplantation. 2004;77:1540–1545. [PubMed]
29. Cavallari A, Cillo U, Nardo B, Filipponi F, Gringeri E, Montalti R, Vistoli F, D'amico F, Faenza A, Mosca F, et al. A multicenter pilot prospective study comparing Celsior and University of Wisconsin preserving solutions for use in liver transplantation. Liver Transpl. 2003;9:814–821. [PubMed]
30. Erhard J, Lange R, Scherer R, Kox WJ, Bretschneider HJ, Gebhard MM, Eigler FW. Comparison of histidine-tryptophan-ketoglutarate (HTK) solution versus University of Wisconsin (UW) solution for organ preservation in human liver transplantation. A prospective, randomized study. Transpl Int. 1994;7:177–181. [PubMed]
31. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124–1136. [PubMed]
32. Hawaleshka A, Jacobsohn E. Ischaemic preconditioning: mechanisms and potential clinical applications. Can J Anaesth. 1998;45:670–682. [PubMed]
33. Banga NR, Homer-Vanniasinkam S, Graham A, Al-Mukhtar A, White SA, Prasad KR. Ischaemic preconditioning in transplantation and major resection of the liver. Br J Surg. 2005;92:528–538. [PubMed]
34. Hausenloy DJ, Yellon DM. Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res. 2008;79:377–386. [PubMed]
35. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation. 1993;87:893–899. [PubMed]
36. Koti RS, Seifalian AM, McBride AG, Yang W, Davidson BR. The relationship of hepatic tissue oxygenation with nitric oxide metabolism in ischemic preconditioning of the liver. FASEB J. 2002;16:1654–1656. [PubMed]
37. Kanoria S, Jalan R, Davies NA, Seifalian AM, Williams R, Davidson BR. Remote ischaemic preconditioning of the hind limb reduces experimental liver warm ischaemia-reperfusion injury. Br J Surg. 2006;93:762–768. [PubMed]
38. Tapuria N, Junnarkar SP, Dutt N, Abu-Amara M, Fuller B, Seifalian AM, Davidson BR. Effect of remote ischemic preconditioning on hepatic microcirculation and function in a rat model of hepatic ischemia reperfusion injury. HPB (Oxford) 2009;11:108–117. [PubMed]
39. Kanoria S, Mehta NN, Seifalian A, Sharma D, Davidson B. Effect of remote ischemic preconditioning on liver injury in patients undergoing hepatectomy for colorectal metastasis - A single center randomised controlled trial. Society of Academic & Research Surgery. London: Yearbook; 2010. p. 45.
40. Kaur S, Jaggi AS, Singh N. Molecular aspects of ischaemic postconditioning. Fundam Clin Pharmacol. 2009;23:521–536. [PubMed]
41. Zhao ZQ, Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. Cardiovasc Res. 2006;70:200–211. [PubMed]
42. Santos CH, Pontes JC, Miiji LN, Nakamura DI, Galhardo CA, Aguena SM. Postconditioning effect in the hepatic ischemia and reperfusion in rats. Acta Cir Bras. 2010;25:163–168. [PubMed]
43. Zhang WX, Yin W, Zhang L, Wang LH, Bao L, Tuo HF, Zhou LF, Wang CC. Preconditioning and postconditioning reduce hepatic ischemia-reperfusion injury in rats. Hepatobiliary Pancreat Dis Int. 2009;8:586–590. [PubMed]
44. Wang N, Lu JG, He XL, Li N, Qiao Q, Yin JK, Ma QJ. Effects of ischemic postconditioning on reperfusion injury in rat liver grafts after orthotopic liver transplantation. Hepatol Res. 2009;39:382–390. [PubMed]
45. Li CM, Zhang XH, Ma XJ, Luo M. Limb ischemic postconditioning protects myocardium from ischemia-reperfusion injury. Scand Cardiovasc J. 2006;40:312–317. [PubMed]
46. Glantzounis GK, Yang W, Koti RS, Mikhailidis DP, Seifalian AM, Davidson BR. Continuous infusion of N-acetylcysteine reduces liver warm ischaemia-reperfusion injury. Br J Surg. 2004;91:1330–1339. [PubMed]
47. Junnarkar SP, Tapuria N, Dutt N, Fuller B, Seifalian AM, Davidson BR. Bucillamine improves hepatic microcirculation and reduces hepatocellular injury after liver warm ischaemia-reperfusion injury. HPB (Oxford) 2009;11:264–273. [PubMed]
48. Adam R, Astarcioglu I, Castaing D, Bismuth H. Ringer's lactate vs serum albumin as a flush solution for UW preserved liver grafts: results of a prospective randomized study. Transplant Proc. 1991;23:2374–2375. [PubMed]
49. Arora AS, Nichols JC, DeBernardi M, Steers JL, Krom RA, Gores GJ. Glycine rinse protects against liver injury during transplantation. Transplant Proc. 1999;31:505–506. [PubMed]
50. Bachmann S, Bechstein WO, Keck H, Lemmens HP, Brandes N, John AK, Lemasters JJ, Neuhaus P. Pilot study: Carolina Rinse Solution improves graft function after orthotopic liver transplantation in humans. Transplant Proc. 1997;29:390–392. [PubMed]
51. Baskin-Bey ES, Washburn K, Feng S, Oltersdorf T, Shapiro D, Huyghe M, Burgart L, Garrity-Park M, van Vilsteren FG, Oliver LK, et al. Clinical Trial of the Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury. Am J Transplant. 2007;7:218–225. [PubMed]
52. Biasi F, Poli G, Salizzoni M, Cerutti E, Battista S, Mengozzi G, Zamboni F, Franchello A, Molino G, Chiarpotto E, et al. Effect of perioperative infusion of antioxidants on neutrophil activation during liver transplantation in humans. Transplant Proc. 2002;34:755–758. [PubMed]
53. Bogetti D, Jarzembowski TM, Sankary HN, Manzelli A, Knight PS, Chejfec G, Cotler S, Oberholzer J, Testa G, Benedetti E. Hepatic ischemia/reperfusion injury can be modulated with thymoglobulin induction therapy. Transplant Proc. 2005;37:404–406. [PubMed]
54. Bogetti D, Sankary HN, Jarzembowski TM, Manzelli A, Knight PS, Thielke J, Chejfec G, Cotler S, Oberholzer J, Testa G, et al. Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury. Clin Transplant. 2005;19:507–511. [PubMed]
55. Boudjema K, Ellero B, Barguil Y, Fruh S, Altieri M, Kerr J, Wolf P, Jaeck D, Cinqualbre J. Addition of reduced glutathione to UW solution: clinical impact in liver transplantation. Transplant Proc. 1991;23:2341–2343. [PubMed]
56. Bromley PN, Cottam SJ, Hilmi I, Tan KC, Heaton N, Ginsburg R, Potter DR. Effects of intraoperative N-acetylcysteine in orthotopic liver transplantation. Br J Anaesth. 1995;75:352–354. [PubMed]
57. Falasca L, Tisone G, Orlando G, Baiocchi L, Vennerecci G, Anselmo A, Torri E, Di Paolo D, Strati F, Casciani CU, et al. Tauroursodeoxycholate reduces ischemic damage in human allografts: a biochemical and ultrastructural study. Transplant Proc. 2000;32:49–50. [PubMed]
58. Falasca L, Tisone G, Palmieri G, Anselmo A, Di Paolo D, Baiocchi L, Torri E, Orlando G, Casciani CU, Angelico M. Protective role of tauroursodeoxycholate during harvesting and cold storage of human liver: a pilot study in transplant recipients. Transplantation. 2001;71:1268–1276. [PubMed]
59. Fisher RA, Posner MP, Shiffman ML, Mills AS, Contos MJ, Beeston J, Bowman T, Wolfe L, Lee HM. Adenosine rinse in human orthotopic liver transplantation: results of a randomized, double-blind trial. Int J Surg Investig. 1999;1:55–66. [PubMed]
60. Henley KS, Lucey MR, Normolle DP, Merion RM, McLaren ID, Crider BA, Mackie DS, Shieck VL, Nostrant TT, Brown KA. A double-blind, randomized, placebo-controlled trial of prostaglandin E1 in liver transplantation. Hepatology. 1995;21:366–372. [PubMed]
61. Himmelreich G, Hundt K, Neuhaus P, Bechstein WO, Roissant R, Riess H. Evidence that intraoperative prostaglandin E1 infusion reduces impaired platelet aggregation after reperfusion in orthotopic liver transplantation. Transplantation. 1993;55:819–826. [PubMed]
62. Khan AW, Fuller BJ, Shah SR, Davidson BR, Rolles K. A prospective randomized trial of N-acetyl cysteine administration during cold preservation of the donor liver for transplantation. Ann Hepatol. 2005;4:121–126. [PubMed]
63. Klein AS, Cofer JB, Pruett TL, Thuluvath PJ, McGory R, Uber L, Stevenson WC, Baliga P, Burdick JF. Prostaglandin E1 administration following orthotopic liver transplantation: a randomized prospective multicenter trial. Gastroenterology. 1996;111:710–715. [PubMed]
64. Klein M, Geoghegan J, Wangemann R, Böckler D, Schmidt K, Scheele J. Preconditioning of donor livers with prostaglandin I2 before retrieval decreases hepatocellular ischemia-reperfusion injury. Transplantation. 1999;67:1128–1132. [PubMed]
65. Koelzow H, Gedney JA, Baumann J, Snook NJ, Bellamy MC. The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. Anesth Analg. 2002;94:824–829, table of contents. [PubMed]
66. Lang JD Jr, Teng X, Chumley P, Crawford JH, Isbell TS, Chacko BK, Liu Y, Jhala N, Crowe DR, Smith AB, et al. Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest. 2007;117:2583–2591. [PMC free article] [PubMed]
67. Neumann UP, Kaisers U, Langrehr JM, Glanemann M, Müller AR, Lang M, Jörres A, Settmacher U, Bechstein WO, Neuhaus P. Administration of prostacyclin after liver transplantation: a placebo controlled randomized trial. Clin Transplant. 2000;14:70–74. [PubMed]
68. Neumann UP, Kaisers U, Langrehr JM, Glanemann M, Müller AR, Lang M, Platz KP, Settmacher U, Steinmüller T, Bechstein WO, et al. Reduction of reperfusion injury with prostacyclin I2 after liver transplantation. Transplant Proc. 1999;31:1029–1030. [PubMed]
69. Neumann UP, Kaisers U, Langrehr JM, Lang M, Glanemann M, Raakow R, Steinmüller T, Settmacher U, Müller AR, Bechstein WO, et al. Treatment with PGE1 in patients after liver transplantation. Transplant Proc. 1998;30:1869–1870. [PubMed]
70. Plöchl W, Krenn CG, Pokorny H, Pezawas L, Pezawas T, Steltzer H. The use of the antioxidant tirilazad mesylate in human liver transplantation: is there a therapeutic benefit? Intensive Care Med. 1999;25:616–619. [PubMed]
71. Sanchez-Urdazpal L, Gores GJ, Lemasters JJ, Thurman RG, Steers JL, Wahlstrom HE, Hay EI, Porayko MK, Wiesner RH, Krom RA. Carolina rinse solution decreases liver injury during clinical liver transplantation. Transplant Proc. 1993;25:1574–1575. [PubMed]
72. Srinivasa R, Morris A, Enright SM, Bellamy MC. Intravenous magnesium does not modify ischaemia-reperfusion syndrome in orthotopic liver transplantation. Br J Anaesth. 1997;79:686P.
73. St Peter SD, Post DJ, Rodriguez-Davalos MI, Douglas DD, Moss AA, Mulligan DC. Tacrolimus as a liver flush solution to ameliorate the effects of ischemia/reperfusion injury following liver transplantation. Liver Transpl. 2003;9:144–149. [PubMed]
74. Steib A, Freys G, Collin F, Launoy A, Mark G, Boudjema K. Does N-acetylcysteine improve hemodynamics and graft function in liver transplantation? Liver Transpl Surg. 1998;4:152–157. [PubMed]
75. Thies JC, Teklote J, Clauer U, Töx U, Klar E, Hofmann WJ, Herfarth C, Otto G. The efficacy of N-acetylcysteine as a hepatoprotective agent in liver transplantation. Transpl Int. 1998;11 Suppl 1:S390–S392. [PubMed]
76. Thies H, Wiemers K. [Results of neurological study and EEG findings in patients with congenital heart defects treated by surgery under hypothermia.] Thoraxchirurgie. 1961;8:531–547. [PubMed]
77. Weigand MA, Plachky J, Thies JC, Spies-Martin D, Otto G, Martin E, Bardenheuer HJ. N-acetylcysteine attenuates the increase in alpha-glutathione S-transferase and circulating ICAM-1 and VCAM-1 after reperfusion in humans undergoing liver transplantation. Transplantation. 2001;72:694–698. [PubMed]
78. Ke B, Lipshutz GS, Kupiec-Weglinski JW. Gene therapy in liver ischemia and reperfusion injury. Curr Pharm Des. 2006;12:2969–2975. [PubMed]
79. Guarrera JV, Henry SD, Samstein B, Odeh-Ramadan R, Kinkhabwala M, Goldstein MJ, Ratner LE, Renz JF, Lee HT, Brown RS Jr, et al. Hypothermic machine preservation in human liver transplantation: the first clinical series. Am J Transplant. 2010;10:372–381. [PubMed]
80. Brockmann J, Reddy S, Coussios C, Pigott D, Guirriero D, Hughes D, Morovat A, Roy D, Winter L, Friend PJ. Normothermic perfusion: a new paradigm for organ preservation. Ann Surg. 2009;250:1–6. [PubMed]
81. Jain S, Lee SH, Korneszczuk K, Culberson CR, Southard JH, Berthiaume F, Zhang JX, Clemens MG, Lee CY. Improved preservation of warm ischemic livers by hypothermic machine perfusion with supplemented University of Wisconsin solution. J Invest Surg. 2008;21:83–91. [PubMed]
82. Wall RJ, Shani M. Are animal models as good as we think? Theriogenology. 2008;69:2–9. [PubMed]
83. Gurusamy KS, Gluud C, Nikolova D, Davidson BR. Assessment of risk of bias in randomized clinical trials in surgery. Br J Surg. 2009;96:342–349. [PubMed]

Articles from World Journal of Gastroenterology : WJG are provided here courtesy of Baishideng Publishing Group Inc